Showing 5431-5440 of 9431 results for "".
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- Global Derm Market Reaches $11.6 Billionhttps://practicaldermatology.com/news/20120224-global_derm_market_reaches_116_billion/2459867/The global prescription dermatologic therapy market grew 6.2% from 2009 to 2001, to reach $11.6 billion. A new MarketWatch.com. report notes that the most dramatic gains were in the antiaging/photodamage, hair loss and hair removal, psoriasi
- Ulthera to Expand Operationshttps://practicaldermatology.com/news/20120210-ulthera_to_expand_operations/2459868/Ulthera, Inc. (www.ultherapy.com) is expanding its operations to include the manufacturing of various components of its technology, part of a growth plan anticipated to create more than 100 new, high-wage jobs and result in $1.68 milli
To Be Shorr: Save Money in Your Practice
https://practicaldermatology.com/topics/practice-management/to-be-shorr-save-money-in-your-practice/18653/To Be Shorr: Save money in your practice. There are many ways you can save money in your practice—often by taking advantage of opportunities offered by your vendors. Find out what services are available to your aesthetic practice and you can grow your cosmetic/plastic surgery office while saving monTo Be Shorr: Use Call Tracking Numbers to Measure Your Marketing ROI
https://practicaldermatology.com/topics/practice-management/to-be-shorr-use-call-tracking-numbers-to-measure-your-marketing-roi/18604/Tracking ROI on your marketing initiatives is an important but sometimes challenging undertaking. In this edition of "To Be Shorr," Mara Shorr, BS, CAC II-V shares tips for easily tracking your investments, including the use of call tracking numbers.To Be Shorr: Your receptionist is director of first impressions
https://practicaldermatology.com/topics/practice-management/to-be-shorr-your-receptionist-is-director-of-first-impressions/18603/Th best physicians and surgeons can see their practice fall apart if they lack good staff. The receptionist is often the first contact a patient has with your practice. Think of this individual as your director of first impressions, says Mara Shorr, BS, CAC II-V.To Be Shorr: Importance of Using Technology to Its Fullest Extent
https://practicaldermatology.com/topics/practice-management/to-be-shorr-importance-of-using-technology-to-its-fullest-extent/18605/Some of the administrative tasks that bog down a practice can be automated—and your existing vendors may have the applications and technology you need to make it happen. Be sure to investigate the services your vendors provide, many of which you already pay for, to make the most of your practice tecAn Overview of Topical Therapies for Managing Pediatric AD
https://practicaldermatology.com/topics/atopic-dermatitis/an-overview-of-topical-ththerapies-for-managing-pediatric-ad/54375/Moisturization is foundational in AD management; no specific formulation has demonstrated superiority, and excessive bathing may worsen disease via increased transepidermal water loss. Topical corticosteroids and calcineurin inhibitors remain first-line due to strong efficacy data, cost-effectiveneSelecting the Optimal JAK Inhibitor for Alopecia Areata
https://practicaldermatology.com/topics/hair-nails/selecting-the-optimal-jak-inhibitor-for-alopecia-areata/67265/Since 2022, the US Food and Drug Administration (FDA) has approved three oral JAK inhibitors: baricitinib, ritlecitinib, and deuruxolitinib.Acquired Dermal Macular Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/acquired-dermal-macular-hyperpigmentation/67257/Acquired dermal macular hyperpigmentation (ADMH) encompasses a group of chronic acquired pigmentary dermatoses characterized by the presence of dermal pigmentation.